Abcam, ab283962, Anti-SARS-CoV-2 orf7a antibody [EPR24850-55]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal NS7A antibody. Suitable for I-ELISA, WB, ICC/IF, IHC-P and reacts with Recombinant full length protein - SARS-CoV-2, SARS-CoV-2, Recombinant fragment - SARS-CoV-2, Transfected cell line - SARS-CoV-2 samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24850-55,
Isotype:IgG,
Carrier free:No,
Reacts with:SARS-CoV-2,
Applications:WB, IHC-P, ICC/IF, I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Not suitable for FC (intra).

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SARS-CoV-2 orf7a also known as accessory protein 7a plays a mechanical role in the virus's lifecycle. It is a small transmembrane protein with a molecular mass of approximately 11 kDa. SARS-CoV-2 orf7a expresses within infected host cells mainly within the endoplasmic reticulum and the Golgi apparatus. It acts during the viral assembly and release processes interacting with other viral proteins to facilitate these functions.
Biological function summary
SARS-CoV-2 orf7a contributes to pathogenesis by antagonizing host immune responses. The protein has the ability to inhibit the activity of bone marrow stromal antigen 2 (BST2) also known as tetherin which prevents virus budding. By doing so orf7a enables the virus to evade an important part of the host's immune defense. It functions independently and does not appear to be part of any multi-protein complex.
Pathways
Orf7a takes part in modulating immune evasion pathways that involve the suppression of type I interferon responses. The protein is related to the pathway that regulates host immune defenses and its suppression of BST2 highlights this action. While orf7a does not directly interact with many host pathway proteins it affects the overall viral regulation of host immune response.
SARS-CoV-2 orf7a is important in the context of COVID-19. Its function in inhibiting host immune defenses can exacerbate the severity of the disease as it aids the virus in escaping immune detection. Through its connection with the modulation of immune responses orf7a interacts with relevant host proteins indirectly affecting the course of the disease and contributing to viral pathogenicity.